Catalyzing Cardiovascular Health Innovation through Urban Interventions and Collaborative Research
Cardiovascular health innovation is at the forefront of the Innovative Health Initiative (IHI), the world’s largest public-private partnership in life sciences, which succeeds the Innovative Medicines Initiative (IMI). Key projects from IHI Call 8, such as Cities@Heart, target cardiovascular disease (CVD) prevention in urban areas where three-quarters of the EU population lives, while BRIDGE tests regulatory sandboxes for novel technologies. These efforts, backed by substantial EU and industry funding, accelerate cardiovascular health innovation from research to real-world impact, with most projects aiming for completion by 2030. For insights into this public-private partnership driving progress, see the detailed overview.
Piloting CVD Prevention Across Seven Cities
Cities@Heart exemplifies IHI’s targeted cardiovascular health innovation for CVD, the top global killer, by developing interventions in Belfast (Northern Ireland), Birmingham (England), Cork (Ireland), Izmir (Turkey), Łódź (Poland), Udine (Italy), and Utrecht (the Netherlands). With €15.2 million in EU funding matched by €13.4 million from industry—totaling over €28.5 million—the project supports the EU Safe Hearts Plan, identifying scalable urban strategies for prevention, detection, diagnosis, and treatment.
Testing Flexible Regulatory Sandboxes
BRIDGE tackles regulatory barriers for AI, digital health, and biological therapies via the Modular Operational Sandbox for Healthcare Innovation and Compliance (MOSAIC). Funded by €5.2 million from the EU and €4.3 million from industry, it adapts mechanisms from other sectors to fast-track health tech approvals as innovations outpace traditional frameworks.
Embedding Patient Voices in Lifecycles
UNIFIED and PROBE prioritize patient outcomes across development, health technology assessment (HTA), reimbursement, and practice. UNIFIED builds a framework for patient input with €12.6 million EU, €9.7 million industry, and €3.9 million partner funding. PROBE uses AI to harmonize datasets for knee osteoarthritis subgroups, backed by €14 million EU, €13.2 million industry, and €4.3 million partner funds, shifting focus to experience-based endpoints.
Accelerating AI in Drug Discovery and Care
IHI Call 9 projects LIGAND-AI and GUIDE-AI leverage AI for efficiency. LIGAND-AI models protein-molecule interactions across billions of compounds, creating an open dataset with €29.9 million EU, €30.2 million industry, and €2.5 million partner funding. GUIDE-AI builds “guideline navigators” for heart failure, kidney disease, COPD, and asthma using large language models, supported by €4.9 million EU and €4.2 million industry.
Reviving Treatments Against AMR
END2AMR combats antimicrobial resistance (AMR) for tuberculosis, bacterial infections, diarrhoeal diseases, and wounds with €15 million each from EU and industry. It bolsters research to sustain options amid antibiotic failures.
Unlocking Health Economics Gains
IHI mobilizes universities, companies, patients, and stakeholders via competitive calls tied to its Strategic Research and Innovation Agenda, building on IMI’s legacy. Balanced funding de-risks therapies, streamlines regulations and HTA, and boosts reimbursement. Urban CVD models and AI pipelines cut costs and timelines; sandboxes speed AI-digital market entry; patient endpoints enhance pricing value, positioning Europe for 2030 health targets.
